In hepatocellular carcinoma (HCC) models (Hep3B and HepG2 cells), inhibition of either GNPAT or USP30 significantly reduces DRP1 protein levels, triggering mitochondrial fusion and suppressing cancer cell proliferation and HCC progression. Here, DNM1L is linked to hepatocellular carcinoma.